| A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) (NCT05107128) | Supernus Pharmaceuticals, Inc. | 2022-01-26 |
| HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States (NCT03628235) | CHDI Foundation, Inc. | 2020-06-21 |
| Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease (NCT04120493) | UniQure Biopharma B.V. | 2019-09-06 |
| Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease (NCT03664804) | Hoffmann-La Roche | 2018-12-05 |
| A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine) (NCT02509793) | William Ondo, MD | 2018-08-01 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) (NCT03342053) | Hoffmann-La Roche | 2018-01-02 |
| Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD (NCT03306888) | Teachers College, Columbia University | 2017-10-10 |
| Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (NCT03225833) | Wave Life Sciences USA, Inc. | 2017-07-17 |
| Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (NCT03225846) | Wave Life Sciences USA, Inc. | 2017-07-17 |
| FuRST 2.0 Cognitive Pre-Testing (NCT02881931) | CHDI Foundation, Inc. | 2017-02-28 |
| Exploring Computerised Cognitive Training for People With Huntington's Disease (NCT02990676) | Cardiff University | 2017-01-25 |
| HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease (NCT02855476) | University College, London | 2017-01-01 |
| PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease (NCT02263430) | Beijing Pins Medical Co., Ltd | 2016-12-01 |
| Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. (NCT02750982) | Brown, Theodore R., M.D., MPH | 2016-07-01 |
| Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease (NCT02507284) | Azevan Pharmaceuticals | 2016-05-10 |
| Functional Imaging of Social Cognition in Premanifest Huntington's Disease (NCT02551705) | Universitaire Ziekenhuizen KU Leuven | 2015-10-01 |
| Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers (NCT02956148) | CHDI Foundation, Inc. | 2015-09-06 |
| A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi (NCT02481674) | Vaccinex Inc. | 2015-07-01 |
| ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders (NCT02252380) | InSightec | 2015-05-01 |
| Electronic-health Application To Measure Outcomes REmotely Clinical Trial (NCT02418546) | Massachusetts General Hospital | 2015-04-01 |
| Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021 (NCT02342548) | Pfizer | 2015-02-25 |
| Working Memory Training in Huntington's Disease (NCT02926820) | York University | 2015-02-01 |
| Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging (NCT02550275) | University Hospital, Angers | 2015-01-01 |
| A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod (NCT02215616) | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-10-28 |
| Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers (NCT02208934) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2014-09-01 |
| Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease (NCT02197130) | Pfizer | 2014-09-01 |
| Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients (NCT02231580) | Ipsen | 2014-09-01 |
| Brain Stimulation in Movement Disorders (NCT02216474) | Birmingham and Solihull Mental Health NHS Foundation Trust | 2014-09-01 |
| A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease (NCT02006472) | Prilenia | 2014-02-28 |
| Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease (NCT02074410) | Omeros Corporation | 2014-01-01 |
| Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease (NCT01806896) | Pfizer | 2013-09-01 |
| At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions (NCT01931644) | Sanguine Biosciences | 2013-07-01 |
| [PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET. (NCT02061722) | CHDI Foundation, Inc. | 2013-01-01 |
| Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort (NCT01574053) | CHDI Foundation, Inc. | 2012-07-01 |
| Apathy Cure Through Bupropion in Huntington's Disease (NCT01914965) | Charite University, Berlin, Germany | 2012-06-01 |
| Exercise Effects in Huntington's Disease (NCT01879267) | University of Zurich | 2012-01-01 |
| A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery (NCT01592552) | Sanguine Biosciences | 2011-11-01 |
| A Phase II Safety and Tolerability Study With SEN0014196 (NCT01521585) | Siena Biotech S.p.A. | 2011-11-01 |
| A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease (NCT01485965) | Siena Biotech S.p.A. | 2011-11-01 |
| Neuroprotection by Cannabinoids in Huntington's Disease (NCT01502046) | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 2011-09-01 |
| Cognitive Assessment Battery (CAB) Beta Study (NCT01290861) | CHDI Foundation, Inc. | 2011-02-01 |
| Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103) (NCT02101957) | University Hospital, Angers | 2010-10-01 |
| Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease (NCT01451463) | Ohio State University | 2010-04-01 |
| Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability (NCT01411163) | Massachusetts General Hospital | 2010-04-01 |
| Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL) (NCT00920699) | Johns Hopkins University | 2010-02-01 |
| Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea (NCT01019473) | Novartis Pharmaceuticals | 2009-11-01 |
| A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin (NCT00990613) | Pfizer | 2009-10-01 |
| Escalating Dose Study in Healthy Volunteers With SEN0014196 (NCT01521832) | Siena Biotech S.p.A. | 2009-10-01 |
| A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users (NCT00975481) | Pfizer | 2009-10-01 |
| Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) (NCT00712426) | Massachusetts General Hospital | 2009-09-01 |
| A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers (NCT00931073) | Pfizer | 2009-07-01 |
| Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study (NCT01411150) | Massachusetts General Hospital | 2009-05-01 |
| Deep Brain Stimulation of the Globus Pallidus in Huntington's Disease (NCT00902889) | Heinrich-Heine University, Duesseldorf | 2009-05-01 |
| Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon (NCT00907595) | Massachusetts General Hospital | 2009-05-01 |
| A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects (NCT00825084) | Pfizer | 2009-02-01 |
| A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects (NCT00827034) | Pfizer | 2009-02-01 |
| A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function (NCT00824590) | Pfizer | 2009-02-01 |
| The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease (NCT01735981) | Anne Kloos | 2008-06-01 |
| A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease (NCT00665223) | Teva Branded Pharmaceutical Products R&D, Inc. | 2008-04-24 |
| A Study of the Novel Drug Dimebon in Patients With Huntington's Disease (NCT00497159) | Medivation, Inc. | 2007-07-01 |
| Individuals Patterns of Disclosure About Huntington s Disease (HD) and the Association With Adaptation to HD (NCT00491842) | National Human Genome Research Institute (NHGRI) | 2007-06-22 |
| Safety Study of the Novel Drug Dimebon to Treat Patients With Huntington's Disease (NCT00387270) | Medivation, Inc. | 2006-10-01 |
| Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease (NCT00670709) | University of California, Los Angeles | 2006-09-01 |
| Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD) (NCT00212316) | University of Rochester | 2005-08-01 |
| Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease (NCT01860339) | Peggy C Nopoulos | 2005-07-01 |
| Study of Memantine to Treat Huntington's Disease (NCT00652457) | Jody Corey-Bloom, MD, PhD | 2004-11-23 |
| Effects of Music Therapy on Huntington's Disease (NCT00178360) | University of Rochester | 2004-07-01 |
| REGISTRY - an Observational Study of the European Huntington's Disease Network (EHDN) (NCT01590589) | European Huntington's Disease Network | 2004-06-01 |
| Creatine Therapy for Huntington's Disease (NCT00026988) | National Center for Complementary and Integrative Health (NCCIH) | 2001-10-01 |
| Minocycline in Patients With Huntington's Disease (NCT00029874) | FDA Office of Orphan Products Development | 2001-09-01 |
| Treatment of Huntington's Chorea With Amantadine (NCT00001930) | National Institute of Neurological Disorders and Stroke (NINDS) | 1999-04-01 |
| Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease (NCT00004753) | National Center for Research Resources (NCRR) | 1993-08-01 |
| Efficacy and Safety of Tetrabenazine in Chorea (NCT00219804) | Prestwick Pharmaceuticals | |